Monoprophylaxis with cephalosporins for transrectal prostate biopsy after the fluoroquinolone-era: A multi-institutional comparison of infectious complications

2021 ◽  
Vol 79 ◽  
pp. S1408
Author(s):  
M. Wenzel ◽  
J. Von Hardenberg ◽  
M.N. Welte ◽  
B. Hoeh ◽  
C. Wittler ◽  
...  
Keyword(s):  
Prostate Biopsy ◽  
Infectious Complications ◽  
Transrectal Prostate Biopsy

scholarly journals Impact of Rectal Swabs on Infectious Complications after Transrectal Prostate Biopsy

2016 ◽  
Vol 97 (3) ◽  
pp. 340-346 ◽  
Author(s):  
Carlos Gustavo Trujillo ◽  
Mauricio Plata ◽  
Juan Ignacio Caicedo ◽  
Juan Guillermo Cataño Cataño ◽  
Angela Marcela Mariño Alvarez ◽  
...  
Keyword(s):  
Prostate Biopsy ◽  
Infectious Complications ◽  
Rectal Swabs ◽  
Transrectal Prostate Biopsy

scholarly journals Cutting to the Core of the Issue: Emerging Strategies To Reduce Prostate Biopsy-Related Infections

2016 ◽  
Vol 54 (10) ◽  
pp. 2431-2435 ◽  
Author(s):  
Robin R. Chamberland
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Prostate Biopsy ◽  
Current Trend ◽  
The United States ◽  
Infectious Complications ◽  
Published Data ◽  
The Core ◽  
Link Type ◽  
Transrectal Prostate Biopsy

Over 1 million men undergo biopsy in the United States each year to evaluate for prostate cancer (S. Loeb, H. B. Carter, S. I. Berndt, W. Ricker, and E. M. Schaeffer, J Urol 186:1830–1834, 2011,http://dx.doi.org/10.1016/j.juro.2011.06.057). In recent years, there has been a rise in infectious complications related to these procedures. This review aims to provide an overview of the guidelines that direct transrectal prostate biopsy, to describe associated infection, and to evaluate the published data driving the current trend toward prebiopsy screening for resistant organisms.

scholarly journals Acute Aortic Valve Rupture from Infective Endocarditis after Transrectal Prostate Biopsy: A Call to Revise the AHA Guidelines for Prevention of Infective Endocarditis

2013 ◽  
Vol 6 ◽  
pp. CCRep.S10503 ◽  
Author(s):  
Julia Ansari ◽  
Gurkaran Singh Garcha ◽  
Henry Huang ◽  
Faisal G. Bakaeen ◽  
Salim S. Virani ◽  
...  
Keyword(s):  
Infective Endocarditis ◽  
Aortic Valve ◽  
Prostate Biopsy ◽  
Transrectal Ultrasound ◽  
Febrile Illness ◽  
Heart Association ◽  
Infectious Complications ◽  
Medical Work ◽  
Intermittent Fever ◽  
Transrectal Prostate Biopsy

We describe the case of a 63-year-old man with a known murmur who presented with a 4-month history of intermittent fever and a progressive reduction in energy level after a transrectal prostate biopsy (TRPB). He subsequently presented with acute heart failure secondary to aortic valve cusp rupture caused by endocarditis and underwent urgent aortic valve surgery. The 2008 American College of Cardiology/American Heart Association Guideline update on infective endocarditis has narrowed the use of antibiotic prophylaxis before most accepted dental procedures and continues to recommend against prophylaxis before genitourinary or gastrointestinal procedures. In contrast, the American Urological Association recommends the use of fluoroquinolones for the prevention of transrectal ultrasound–derived infectious complications. Notably, TRPB is associated with a high frequency of bacteremia and bacteriuria. In our case, an antibiotic course before the procedure and a more meticulous medical work-up after febrile illness might have mitigated the patient's catastrophic medical presentation.

Fluoroquinolone Resistant Rectal Colonization Predicts Risk of Infectious Complications after Transrectal Prostate Biopsy

2014 ◽  
Vol 192 (6) ◽  
pp. 1673-1678 ◽  
Author(s):  
Michael A. Liss ◽  
Stephen A. Taylor ◽  
Deepak Batura ◽  
Deborah Steensels ◽  
Methee Chayakulkeeree ◽  
...  
Keyword(s):  
Prostate Biopsy ◽  
Infectious Complications ◽  
Transrectal Prostate Biopsy ◽  
Rectal Colonization

scholarly journals Options for antibacterial prophylaxis of infectious complications of prostate biopsy

2021 ◽  
Vol 14 (3) ◽  
pp. 150-155
Author(s):  
S.V. Popov ◽  
◽  
I.N. Orlov ◽  
D.Yu. Chernysheva ◽  
T.M. Topuzov ◽  
...  
Keyword(s):  
Antibiotic Prophylaxis ◽  
Prostate Biopsy ◽  
Clinical Guidelines ◽  
Urine Culture ◽  
Infectious Complications ◽  
Antibacterial Prophylaxis ◽  
Scientific Databases ◽  
Transrectal Prostate Biopsy ◽  
Long Time ◽  
Transperineal Biopsy

Introduction. Amount of prostate biopsy procedures rises every year and up to 95% of cases of prostate biopsy is performed via transrectal approach. The incidence of infectious complications of transrectal prostate biopsy reaches up to 17%, while incidence of such complications of transperineal biopsy is about 1%. The majority of international clinical guidelines recommends for obligatory antibiotic prophylaxis prior to prostate biopsy of any approach, but the choice of antibiotic is still debatable. The aim of this review is to sum up the approaches of international urological guidelines to the antibiotic prophylaxis prior to prostate biopsy. Materials and methods. We analyzed the search results in the scientific databases PubMed, Google Scolar, elibrary.ru for the queries «prostate biopsy», «antibacterial prophylaxis» and «guidelines». Results. According to the recommendations of most professional communities, antibacterial prophylaxis of infectious complications of prostate biopsy can be carried out in various ways - once or for a long time, one- or two-component, empirically or on the basis of urine culture on microflora. Conclusion. Despite the differences in the levels of sensitivity and resistance of coliform flora around the world, the clinical guidelines in most countries are uniform in terms of the choice of drugs to reduce the risk of developing infectious complications after prostate biopsy. Approaches to antibacterial prophylaxis after prostate biopsy differ only depending on the type of biopsy access.

scholarly journals Prolonged antibiotic therapy increases risk of infection after transrectal prostate biopsy: A case report after pancreasectomy and review of the literature

2014 ◽  
Vol 86 (4) ◽  
pp. 387 ◽  
Author(s):  
Guevar Maselli ◽  
Giacomo Tucci ◽  
Daniele Mazzaferro ◽  
Asim Ettamimi ◽  
Giulia Sbrollini ◽  
...  
Keyword(s):  
High Risk ◽  
Prostate Biopsy ◽  
Pancreatic Surgery ◽  
Infectious Complications ◽  
Major Surgery ◽  
Risk Category ◽  
Resistant Variant ◽  
High Risk Category ◽  
Transrectal Prostate Biopsy ◽  
History Of

Infection due to prostate biopsy afflicted more than 5% of patients and is the most common reason for hospitalization. A large series from US SEER-Medicare reported that men undergoing biopsy were 2.26 times more likely to be hospitalized for infectious complications within 30 days compared with randomly selected controls. The factors predicting a higher susceptibility to infection remain largely unknown but some authors have higlighted in the etiopathogenesis the importance of the augmented prevalence of ciprofloxacin resistant variant of bacteria in the rectum flora. We present one case of sepsis after transrectal prostate biopsy in a patient with history of pancreatic surgery. Based on our experience patients candidated to prostate biopsy with transrectal technique with history of recent major surgery represent an high risk category for infective complication. Also major pancreatic surgery should be consider an high risk category for infection. A transperineal approach and preventive measures (such as rectal swab) should be adopted to reduce biopsy driven infection.

scholarly journals Monoprophylaxis With Cephalosporins for Transrectal Prostate Biopsy After the Fluoroquinolone-Era: A Multi-Institutional Comparison of Severe Infectious Complications

2021 ◽  
Vol 11 ◽  
Author(s):  
Mike Wenzel ◽  
Jost von Hardenberg ◽  
Maria N. Welte ◽  
Samuel Doryumu ◽  
Benedikt Hoeh ◽  
...  
Keyword(s):  
Single Dose ◽  
Prostate Biopsy ◽  
Infectious Complications ◽  
Complication Rates ◽  
Logistic Regression Models ◽  
Prostate Biopsies ◽  
Multiple Doses ◽  
Related Risk ◽  
Transrectal Prostate Biopsy ◽  
Low Incidence

BackgroundTo compare severe infectious complication rates after transrectal prostate biopsies between cephalosporins and fluoroquinolones for antibiotic monoprophylaxis.Material and MethodsIn the multi-institutional cohort, between November 2014 and July 2020 patients received either cefotaxime (single dose intravenously), cefpodoxime (multiple doses orally) or fluoroquinolones (multiple-doses orally or single dose intravenously) for transrectal prostate biopsy prophylaxis. Data were prospectively acquired and retrospectively analyzed. Severe infectious complications were evaluated within 30 days after biopsy. Logistic regression models predicted biopsy-related infectious complications according to antibiotic prophylaxis, application type and patient- and procedure-related risk factors.ResultsOf 793 patients, 132 (16.6%) received a single dose of intravenous cefotaxime and were compared to 119 (15%) who received multiple doses of oral cefpodoxime and 542 (68.3%) who received fluoroquinolones as monoprophylaxis. The overall incidence of severe infectious complications was 1.0% (n=8). No significant differences were observed between the three compared groups (0.8% vs. 0.8% vs. 1.1%, p=0.9). The overall rate of urosepsis was 0.3% and did not significantly differ between the three compared groups as well.ConclusionMonoprophylaxis with third generation cephalosporins was efficient in preventing severe infectious complications after prostate biopsy. Single intravenous dose of cefotaxime and multiday regimen of oral cefpodoxime showed a low incidence of infectious complications <1%. No differences were observed in comparison to fluoroquinolones.

Sign in / Sign up

Export Citation Format

Share Document